Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 6, 2005, Pages 972-982

  Novick, Diego ^a   Bousono, Manuel ^b   Suarez, David ^c   Olivares, Jose M ^d   Montejo, Angel L ^e   Haro, Josep Maria ^c   Edgell, Eric T ^a   Ratcliffe, Mark ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Research and Development Unit   (Spain)

^d UNIVERSITY OF VIGO   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Anticholinergic; Antidepressant; Antipsychotic; Anxiolytic; Concomitant medication; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EUROPE; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 23144466079     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.06.003     Document Type: Article

References (32)

1. K. Benson, and A.J. Hartz A comparison of observational studies and randomised, controlled trials N. Engl. J. Med. 342 2000 1878 1886
2. R.J. Beyth, and R.I. Shorr Epidemiology of adverse drug reactions in the elderly by drug class Drugs Aging 4 1999 231 239
3. J. Bobes, J. Gibert, A. Ciudad, E. Alvarez, F. Cañas, J.L. Carrasco, J. Gascón, J.C. Gómez, and M. Gutiérrez Safety and effectiveness of olanzapine vs. conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 473 481
4. D.E. Casey, D.G. Daniel, A.A. Wassef, K.A. Tracy, P. Wozniak, and K.W. Sommerville Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia Neuropsychopharmacology 28 2003 182 192
5. L. Duggan, M. Fenton, R.M. Dardennes, A. El-Dosoky, and S. Indran Olanzapine for schizophrenia Cochrane Database Syst. Rev., Issue 1 2003 (CD001359)
6. K. Fattinger, M. Roos, P. Vergeres, C. Holenstein, B. Kind, U. Masche, D.N. Stocker, S. Braunschweig, G.A. Kullak-Ublick, R.L. Galeazzi, F. Follath, T. Gasser, and P.J. Meier Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine Br. J. Clin. Pharmacol. 49 2000 158 167
7. U. Halbreich, and L.S. Kahn Hormonal aspects of schizophrenias: an overview Psychoneuroendocrinology 28 Suppl. 2 2003 1 16
8. J. Haro, E.T. Edgell, P.B. Jones, J. Alonso, S. Gavart, K.J. Gregor, P. Wright, and M. Knapp The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment Acta Psychiatr. Scand. 107 2003 222 232
9. J.M. Haro, E.T. Edgell, P. Frewer, J. Alonso, P.B. Jones on behalf of the SOHO Study Group The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment Acta Psychiatr. Scand. 107 Suppl. 416 2003 7 15
10. J.M. Haro, S.A. Kamath, S. Ochoa, D. Novick, K. Rele, A. Fargas, M.J. Rodriguez, R. Rele, J. Orta, A. Kharbeng, S. Araya, M. Gervin, J. Alonso, V. Mavreas, N. Laverentzou, K. Gregor, P.B. Jones on behalf of the SOHO Study Group The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia Acta Psychiatr. Scand. 107 Suppl. 416 2003 16 23
11. J.M. Haro, E.T. Edgell, D. Novick, J. Alonso, L. Kennedy, P.B. Jones, M. Ratcliffe, and A. Breier Effectiveness of antipsychotic treatment for schizophrenia: 6-months results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study Acta Psychiatr. Scand. 111 2005 220 231
12. L. Hosak, and J. Libiger Antiepileptic drugs in schizophrenia: a review Eur. Psychiatr. 17 2002 371 378
13. S. Kasper, and E. Resinger Cognitive effects and antipsychotic treatment Psychoneuroendocrinology 28 Suppl. 1 2003 27 38
14. M. Lambert, J.M. Haro, D. Novick, E.T. Edgell, L. Kennedy, M. Ratcliffe, and D. Naber Olanzapine vs. other antipsychotics in actual outpatient settings: six months tolerability results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study Acta Psychiatr. Scand. 111 2005 232 243
15. S. Leucht, J. McGrath, P. White, and W. Kissling Carbamazepine for schizophrenia and schizoaffective psychoses Cochrane Database Syst. Rev., Issue 3 2002 (CD001258)
16. A. Leung, and P. Chue Sex differences in schizophrenia, a review of the literature Acta Psychiatr. Scand., Suppl. 401 2000 3 38
17. A.R. Lima, K. Soares-Weiser, J. Bacaltchuk, and T.R. Barnes Benzodiazepines for neuroleptic-induced acute akathisia Cochrane Database Syst. Rev., Issue 4 1999 (CD001950)
18. S.R. Marder Overview of partial compliance J. Clin. Psychiatry 64 Suppl. 16 2003 3 9
19. M. Marsalek Tardive drug-induced extrapyramidal syndromes Pharmacopsychiatry 33 Suppl. 1 2000 14 33
20. J. Menzin, L. Boulanger, M. Friedman, J. Mackell, and J.R. Lloyd Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program Psychiatr. Serv. 54 2003 719 723
21. H. Parepally, S. Chakravorty, J. Levine, J.S. Brar, A.M. Patel, and J.W. Baird The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital Prog. Neuro-psychopharmacol. Biol. Psychiatry 26 2002 437 440
22. P. Plasky Antidepressant usage in schizophrenia Schizophr. Bull. 17 1991 649 657
23. J.A. Sacristan, J.C. Gomez, A.L. Montejo, E. Vieta, and K.J. Gregor Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study Clin. Ther. 22 11 2000 583 599
24. H. Silver Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia Expert Opin. Pharmacother. 5 2004 2053 2058
25. M.M. Singh, and S.R. Kay Therapeutic antagonism between anticholinergics and neuroleptics: possible involvement of cholinergic mechanisms in schizophrenia Schizophr. Bull. 4 1978 3 6
26. K.V. Soares, and J.J. McGrath Anticholinergic medication for neuroleptic-induced tardive dyskinesia Cochrane Database Syst. Rev., Issue 2 1997 (CD000204)
27. G.L. Stimmel Benzodiazepines in schizophrenia Pharmacotherapy 16 1996 148S 151S
28. R. Tandon, and J.R. Dequardo Treatment of schizophrenia with anticholinergic medications Am. J. Psychiatry 152 1995 814 815
29. V. Voon, and A.E. Lang Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease Clin. Neuropharmacol. 27 2004 90 92
30. C. Whitehead, S. Moss, A. Cardno, and G. Lewis Antidepressants for people with both schizophrenia and depression Cochrane Database Syst. Rev., Issue 2 2002 (CD002305)
31. C.L. Williams, B.M. Johnstone, J.G. Kesterson, K.A. Javor, and A.D. Schmetzer Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia Med. Care 37 1999 AS81 AS86
32. O.M. Wolkowitz, and D. Pickar Benzodiazepines in the treatment of schizophrenia: a review and reappraisal Am. J. Psychiatry 148 1991 714 726